Completed NA INTERVENTIONAL 2-arm NCT00334022

Fuzeon Viral Decay Pilot Study

A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA

Sponsor: Canadian Immunodeficiency Research Collaborative

Conditions HIV-1

Interventions enfuvirtide

Updated 5 times since 2017 Last updated: Jun 4, 2012 Started: Feb 28, 2006 Primary completion: Jul 31, 2007 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00334022, this NA trial focuses on HIV-1 and remains completed. Sponsored by Canadian Immunodeficiency Research Collaborative, it has been updated 5 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canadian Immunodeficiency Research Collaborative
Hoffmann-La Roche

Data source: Canadian Immunodeficiency Research Collaborative

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada